University licensing deals database extracts

PharmaPlus owns a licensing deals financials database, which solely focuses on licensing deals between research organizations and companies.
From this database PharmaPlus provides standard and customized academia-industry licensing deals database extracts. These extracts offer a valuable intelligence tool for research institutes and start-up companies to support their upcoming licensing deal negotiations, their presentations to potential investors and the writing of their business plans.

With the explosion of activity in early stage life sciences in the last few years, many new programs have been formed at research institutes, which could support the youngest new biotech companies in developing their products and making first steps toward commercialization.
Our PharmaPlus Deal Financials – Research Institutes provides insight into key financial information on almost 100 licensing deals, which were established between 2010 and 2016. Provided are therapy-related licensing deals between research institutes and biopharmaceutical companies that have submitted an IPO-filing in the last 6 years.

See a Sample

Sample (including one licensing deal) for free

Over the past years preclinical academic packages have been seen as good value for startups and their VCs.
Our PharmaPlus Deal Financials – Research Institute Sublicensing offers financial insight into the effect of subsequent sublicensing of research institute inventions by biopharmaceutical companies, that have submitted an IPO-filing in the last 6 years. We provide key financial information on 50 research institute licensing deals and their linked sublicensing deals.

Easy to read

Benchmark your partnering deal terms

Track competitor deal making activity

Access detailed financial information

Monitor deal trends in your areas of interest

Customized extracts

We provide affordable customized university-company deal financials extracts, with a minimum of 5 and a maximum of 25 licensing deals.
For enquiries into deal financials on indications, compound classes or any other criteria of interest to you, we invite you to contact us to discuss your enquiry.